Overview APremilast After FumaRic Acid Ester Treatment Status: Active, not recruiting Trial end date: 2022-05-27 Target enrollment: Participant gender: Summary Patient treatment preference and treatment satisfaction of physicians and patients comparing fumaric acid ester therapy with subsequent apremilast treatment Details Lead Sponsor: AmgenProf. Kristian ReichTreatments: ApremilastThalidomide